Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study

Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors

(2012) Jennifer A Chan et al.   ENDOCRINE-RELATED CANCER

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study

(2012) Larry K Kvols et al.   ENDOCRINE-RELATED CANCER

Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting

(2011) Matthew H. Kulke et al.   JOURNAL OF CLINICAL ONCOLOGY

Pasireotide (SOM230), a Novel Multireceptor-Targeted Somatostatin Analogue, Is Well Tolerated When Administered as a Continuous 7-Day Subcutaneous Infusion in Healthy Male Volunteers

(2011) Stephan Petersenn et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial

(2010) S. Petersenn et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pasireotide Alone or with Cabergoline and Ketoconazole in Cushing's Disease

(2010) Richard A. Feelders et al.   NEW ENGLAND JOURNAL OF MEDICINE

From somatostatin to octreotide LAR: evolution of a somatostatin analogue

(2009) Lowell Anthony et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies

(2009) Gherardo Mazziotti et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Pituitary-Dependent Cushing’s Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial

(2008) M. Boscaro et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Carcinoid Tumors

(2008) S. N. Pinchot et al.   ONCOLOGIST

Pasireotide (SOM230): Development, mechanism of action and potential applications

(2007) Herbert A. Schmid   MOLECULAR AND CELLULAR ENDOCRINOLOGY